Xylem Analyst Price Targets

PRO

Pourquoi cela bouge-t-il ?:Xylem shares are trading lower after the company reported worse-than-expect...

Résultats: Les résultats Q3 2026 ont été publiés aujourd'hui avant l'ouverture du marché

Conférence téléphonique: La conférence téléphonique d'aujourd'hui a commencé il y a 11 heures

Wall Street analyst price targets and consensus rating for Xylem (XYL).

Price Target Range — 13 Quarters

Analyst Consensus — 15 Analysts

11Buy

4Hold

Consensus RatingBuy# Analysts15Avg. Consensus PT$144Upside to Avg. PT+54.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 19, 2026	JP Morgan	Mark Strouse	PT Cut	Neutral	$137→$118
Oct 15, 2026	Mizuho	Brett Linzey	PT Cut	Neutral	$130→$110
Oct 14, 2026	Oppenheimer	Bryan Blair	PT Cut	Outperform	$158→$150
Oct 14, 2026	RBC Capital	Jeffrey Reive	PT Cut	Outperform	$164→$135
Oct 13, 2026	Barclays	William Grippin	PT Cut	Overweight	$159→$139
Oct 12, 2026	Citigroup	Andrew Kaplowitz	PT Cut	Buy	$172→$148
Oct 5, 2026	UBS	Joshua Spector	PT Cut	Neutral	$138→$112
Sep 15, 2026	Wolfe Research	Nigel Coe	Assumes	Peer Perform	—
Aug 24, 2026	Jefferies	Stephen Volkmann	PT Raise	Buy	$145→$150
Aug 13, 2026	UBS	Joshua Spector	PT Raise	Neutral	$135→$138
Jul 30, 2026	UBS	Joshua Spector	PT Raise	Neutral	$129→$135
Jul 29, 2026	Stifel	Nathan Jones	PT Raise	Buy	$157→$160
Jul 29, 2026	Mizuho	Brett Linzey	PT Raise	Neutral	$124→$130
Jul 29, 2026	RBC Capital	Deane Dray	PT Raise	Outperform	$159→$164
Jul 29, 2026	Barclays	William Grippin	PT Raise	Overweight	$154→$159
Jul 29, 2026	Baird	Michael Halloran	PT Raise	Outperform	$163→$165
Jul 20, 2026	Stifel	Nathan Jones	PT Cut	Buy	$159→$157
Jul 16, 2026	RBC Capital	Deane Dray	PT Raise	Outperform	$157→$159
Jun 25, 2026	Jefferies	Stephen Volkmann	Upgrade	Hold→Buy	$130→$140
Apr 29, 2026	UBS	Joshua Spector	PT Raise	Neutral	$132→$133